How has been the historical performance of Cohance Life?

Nov 13 2025 12:35 AM IST
share
Share Via
Cohance Life has shown significant growth from March 2019 to March 2025, with net sales increasing from INR 377.83 crore to INR 2,608.50 crore, and profit after tax rising from INR 109.27 crore to INR 484.24 crore. The company's total assets also grew from INR 1,172.81 crore to INR 3,031.20 crore during this period.
Answer:
The historical performance of Cohance Life shows significant growth in various financial metrics over the years. Breakdown: Cohance Life's net sales have seen a remarkable increase from INR 377.83 crore in March 2019 to INR 2,608.50 crore in March 2025, indicating a strong upward trend. Total operating income followed a similar trajectory, rising from INR 377.83 crore in March 2019 to INR 2,608.50 crore in March 2025. The company's total expenditure, excluding depreciation, also increased significantly, reaching INR 1,811.44 crore in March 2025 from INR 206.28 crore in March 2019. Operating profit (PBDIT) has fluctuated, peaking at INR 866.27 crore in March 2025, while profit before tax reached INR 642.63 crore in the same period. The profit after tax also showed a positive trend, increasing to INR 484.24 crore in March 2025 from INR 109.27 crore in March 2019. The company's total assets grew from INR 1,172.81 crore in March 2019 to INR 3,031.20 crore in March 2025, while total liabilities increased from INR 1,172.81 crore to INR 3,031.20 crore over the same period. Cash flow from operating activities has been relatively stable, with a notable cash flow of INR 288.00 crore in March 2025. Overall, Cohance Life has demonstrated strong growth in sales, profits, and assets, reflecting a robust financial performance over the years.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Cohance Lifesciences Ltd is Rated Sell
Mar 31 2026 10:10 AM IST
share
Share Via
Cohance Lifesciences Ltd is Rated Sell
Mar 20 2026 10:10 AM IST
share
Share Via
Cohance Lifesciences Ltd is Rated Sell
Mar 09 2026 10:10 AM IST
share
Share Via